Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2024-04-25 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
2024年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "安徽安科生物工程(集团)股份有限公司2024 年第一季度报告" which translates to "Anhui Anke Biological Engineering (Group) Co., Ltd. 2024 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial metrics for the first quarter of 2024. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the quarter ending March 31, 2024. It is not a brief announcement or a certification letter but a full financial report for a period shorter than a fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-25 Chinese
关于高级管理人员辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management personnel (Vice President) and related details about her shareholding and continued roles. It does not contain financial data, audit information, or report content. It is a typical announcement of management changes, specifically about senior management personnel. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on management change, confirming this classification.
2024-04-25 Chinese
关于第八届董事会第十一次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions from the 11th meeting of the 8th Board of Directors of Anhui Anke Biotechnology (Group) Co., Ltd. It includes approval of the company's 2024 Q1 report, election of a vice chairman, and appointment of a committee member. The document contains no detailed financial statements or substantive financial data itself but refers to the quarterly report being available on the official disclosure website. It primarily reports board decisions and management changes, including election and appointment of directors and committee members. Therefore, it fits best under Board/Management Information (MANG) rather than an Interim/Quarterly Report (IR) or Annual Report (10-K). The document length is short (1870 characters), and it is an announcement of board resolutions, not the report itself.
2024-04-25 Chinese
关于回购注销部分限制性股票减资暨通知债权人的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the company's repurchase and cancellation of restricted shares, which leads to a reduction in registered capital. It includes details about notifying creditors and the procedures for debt claims related to this capital reduction. The document references previous announcements and shareholder meeting resolutions but does not contain financial statements or detailed financial data. It is primarily a regulatory announcement about capital changes and creditor notification, not a full financial report or earnings release. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length is short and focused on capital structure changes, not a report publication or certification.
2024-04-25 Chinese
安徽天禾律师事务所关于安徽安科生物工程（集团）股份有限公司2023年年度股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2023 Annual General Meeting (AGM) of Anhui Anke Bioengineering (Group) Co., Ltd. It details the procedures for convening and holding the AGM, the qualifications of attendees, the voting procedures, and the results of the votes on various proposals. The document does not contain financial statements or detailed financial performance data but focuses on the legality and validity of the AGM process and resolutions. The document length is 3315 characters, which is relatively short and consistent with a legal opinion or meeting-related document rather than a full report. This type of document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports on the voting results and legality of the AGM proceedings.
2024-04-18 Chinese
2023年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a "2023年度股东大会决议公告" which translates to "2023 Annual General Meeting Resolution Announcement." It details the resolutions passed at the 2023 Annual General Meeting (AGM) of the company, including voting results on various proposals such as financial reports, board reports, profit distribution plans, auditor appointments, and amendments to company bylaws. The document includes attendance details, voting procedures, and legal opinions confirming the validity of the meeting and resolutions. There is no full financial report or detailed financial statements included; rather, it is a formal announcement of the AGM resolutions and voting outcomes. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (9144 characters) is sufficient to contain detailed voting results, not just a brief announcement or a link to a report, so it is not a Report Publication Announcement (RPA).
2024-04-18 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.